RCUS

Arcus Biosciences Inc

Add to Watchlist

Advanced Chart

8.300

-0.110(-1.310%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

8.335

Open

8.160

VWAP

8.27

Vol

503.74K

Mkt Cap

878.85M

Low

8.070

Amount

4.16M

EV/EBITDA(TTM)

Total Shares

90.95M

-51.15M

EV/OCF(TTM)

P/S(TTM)

2.90

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

38.61M

-73.37%

-1.012

-645.39%

37.36M

-4.21%

-0.997

-2.3%

37.36M

-22.17%

-1.019

+1.92%

Estimates Revision

The market is revising Downward the revenue expectations for Arcus Biosciences, Inc. (RCUS) for FY2025, with the revenue forecasts being adjusted by -31.34% over the past three months. During the same period, the stock price has changed by -36.59%.

Revenue Estimates for FY2025

Revise Downward

-31.34%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+9.6%

In Past 3 Month

Stock Price

Go Down

-36.59%

In Past 3 Month

10 Analyst Rating

273.49% Upside

Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 31.00 USD with a low forecast of 17.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

273.49% Upside

Current: 8.300

Low

17.00

Averages

31.00

High

46.00

273.49% Upside

Current: 8.300

Low

17.00

Averages

31.00

High

46.00

Barclays

Peter Lawson

Buy

Maintains

$29 → $14

2025-04-23

New

Reason

Barclays

Peter Lawson

Price Target

$29 → $14

2025-04-23

New

Maintains

Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Hold

Strong Buy

Upgrades

$24

2025-02-26

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$24

2025-02-26

Upgrades

Hold

Strong Buy

Reason

B of A Securities

Jason Zemansky

Hold

Maintains

$22 → $17

2025-02-19

Reason

B of A Securities

Jason Zemansky

Price Target

$22 → $17

2025-02-19

Maintains

Hold

Reason

Morgan Stanley

Terence Flynn

Buy

Maintains

$36 → $25

2025-02-18

Reason

Morgan Stanley

Terence Flynn

Price Target

$36 → $25

2025-02-18

Maintains

Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Hold

Maintains

$20 → $18

2025-02-18

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$20 → $18

2025-02-18

Maintains

Hold

Reason

HC Wainwright & Co.

Emily Bodnar

Hold

Reiterates

$20

2024-11-06

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$20

2024-11-06

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arcus Biosciences Inc (RCUS.N) is -2.07, compared to its 5-year average forward P/E of -5.36. For a more detailed relative valuation and DCF analysis to assess Arcus Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.36

Current PE

-2.07

Overvalued PE

1.47

Undervalued PE

-12.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.66

Current EV/EBITDA

-0.13

Overvalued EV/EBITDA

0.18

Undervalued EV/EBITDA

-9.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

16.51

Current PS

5.76

Overvalued PS

27.06

Undervalued PS

5.97